Clipping of news on Brazilian Culture, Law and Citizenship
02/14/2013
This article was translated by an automatic translation system, and was therefore not reviewed by people.
Experts suggest code of practice for the World Health Organization
Rules should include surveillance and repression, said the report.
U.S. scientists have created a card that changes color according to the drug substance
(Photo: Saint Mary's College / Disclosure)
The fight against the growing problem of fake drugs requires an effort of regulation on pharmaceutical distribution in the United States and greater international cooperation, concluded on Wednesday (13) a report of the American Institute of Medicine (IOM, its acronym in English ).
No country can protect itself from risks to public health from illegal drugs, usually cheaper, independent experts consider the study's authors.
"Counterfeit medicines of poor quality or are a serious threat to public health, as they are ineffective and can cause illness and death, particularly in developing countries where regularly invade the market," said Lawrence Gostin, Professor of Health Law at Georgetown University in Washington, who chairs the group of 12 experts.
"Given the international nature of the production and trade of drugs, each country has an interest and a role to play in ensuring the high quality of these products and the safety of its distribution," said Gostin.
In the United States, for example, several patients were treated with anticancer false Avastin in 2011 and 2012. Avastin is produced by Swiss drugmaker Roche.
These experts have launched an appeal to the World Health Organization (WHO) to promote collaboration and regulatory authorities in different countries, pharmaceutical firms, distributors and civil society.
WHO should lead the development of a code of practice, including rules for monitoring, regulation and enforcement, said the report.
In the United States, these experts consulted by the regulatory agency for food and medicine in the United States (FDA) recommend establishing a system to track medications, from production to distribution, as well as strengthen the regulation that controls the wholesalers of pharmaceutical products, weakest link in the chain.
The report recommends that Congress authorize the FDC to establish a unique identification number of medications, avoiding the introduction in certain stages of fake products.
The deployment of such a system was delayed because of insufficient budget FDA.
Currently, the distribution of drugs in the United States is controlled by state
Source: G1 - News - The Well
Our news are removed entirely from the sites of our partners. For this reason, we can not change their content even in cases of typos.
This article was translated by an automatic translation system, and was therefore not reviewed by people.